Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Montemurro

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Current Opinion in Oncology|April 27, 2011
Treatment of gastrointestinal stromal tumor after imatinib and sunitinibMichael Montemurro, Sebastian Bauer
Seminars in Oncology|March 23, 2011
Clinical experience to date with nilotinib in gastrointestinal stromal tumorsPeter Reichardt, Michael Montemurro
World Journal of Surgery|February 25, 2015
Survival after surgical drainage of malignant pericardial effusionLars Niclauss, Michael Montemurro, René Prêtre
Acta Oncologica (Stockholm, Sweden)|October 30, 2009
Badminton, rectal cancer and 25 kg weight gain during chemotherapyChristian Riklin, Daniel Guntern, Serge Leyvraz, et al.
Interactive Cardiovascular and Thoracic Surgery|March 6, 2018
Sarcoma of the heart: survival after surgeryLars Niclauss, Michael Montemurro, Matthias Kirsch, et al.
Visceral Medicine|December 1, 2018
Gastrointestinal Stromal TumorsPeter Hohenberger, Michael Montemurro, Chandrajit P Raut, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 1, 2015
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective studyHeikki Joensuu, Mikael Eriksson, Juhani Collan, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|June 14, 2013
Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CTSabine Schmidt, Vincent Dunet, Melanie Koehli, et al.
Swiss Medical Weekly|November 24, 2020
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised TherapySeid Hamzic, Stefan Aebi, Markus Joerger, et al.
Blood|September 3, 2010
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinibAmina Haouala, Nicolas Widmer, Michel A Duchosal, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Opinion in Oncology|April 27, 2011
Treatment of gastrointestinal stromal tumor after imatinib and sunitinibMichael Montemurro, Sebastian Bauer
Seminars in Oncology|March 23, 2011
Clinical experience to date with nilotinib in gastrointestinal stromal tumorsPeter Reichardt, Michael Montemurro
World Journal of Surgery|February 25, 2015
Survival after surgical drainage of malignant pericardial effusionLars Niclauss, Michael Montemurro, René Prêtre
Acta Oncologica (Stockholm, Sweden)|October 30, 2009
Badminton, rectal cancer and 25 kg weight gain during chemotherapyChristian Riklin, Daniel Guntern, Serge Leyvraz, et al.
Interactive Cardiovascular and Thoracic Surgery|March 6, 2018
Sarcoma of the heart: survival after surgeryLars Niclauss, Michael Montemurro, Matthias Kirsch, et al.
Visceral Medicine|December 1, 2018
Gastrointestinal Stromal TumorsPeter Hohenberger, Michael Montemurro, Chandrajit P Raut, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 1, 2015
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective studyHeikki Joensuu, Mikael Eriksson, Juhani Collan, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|June 14, 2013
Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CTSabine Schmidt, Vincent Dunet, Melanie Koehli, et al.
Swiss Medical Weekly|November 24, 2020
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised TherapySeid Hamzic, Stefan Aebi, Markus Joerger, et al.
Blood|September 3, 2010
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinibAmina Haouala, Nicolas Widmer, Michel A Duchosal, et al.
Pageof 5